AstraZeneca PLC





Market Closed - London S.E. 16:35:26 12/07/2024 BST 5-day change 1st Jan Change
12,260 GBX +1.32% Intraday chart for AstraZeneca PLC +1.69% +15.66%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Instil Bio Shares Surge Following Rental Agreement with AstraZeneca DJ
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Instil Bio Signs Lease With AstraZeneca Pharmaceuticals at California Facility; Shares Rise After Hours MT
ASTRAZENECA : Deutsche Bank reiterates its Neutral rating ZD
Barclays raises Kerry, cuts Hunting, Wood Group AN
ASTRAZENECA : JP Morgan reaffirms its Buy rating ZD
AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer MT
AstraZeneca: cancer treatment approved by the EU CF
AstraZeneca drug Tagrisso gets EU approval for cancer form AN
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment MT
ASTRAZENECA : Goldman Sachs maintains a Buy rating ZD
ASTRAZENECA : Buy rating from Berenberg ZD
Aptamer shares jump as inks agreement with AstraZeneca AN
Aptamer Group plc Announces New Agreement with AstraZeneca to Evaluate the Optimer Fibrotic Liver Delivery Vehicles for the Targeted Delivery of SiRNA CI
ASTRAZENECA : Jefferies reaffirms its Neutral rating ZD
Deutsche Bank cuts Quilter, ups Polar Capital AN
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June MT
UK Stocks Flat; Manufacturing Sector Remains in Expansion Zone MT
AstraZeneca's Potential Covid-19 Prevention Drug Gets EU Accelerated Assessment MT
AstraZeneca's Imfinzi, Lynparza Combination Recommended for Approval in Europe as Endometrial Cancer Treatment MT
AstraZeneca applies to the EMA for a Covid antibody CF
AstraZeneca: CHMP recommends Imfinzi and Lynparza CF
Stocks called higher ahead of Thursday's election AN
AstraZeneca's Combination Formulation for Endometrial Cancer Gains Support for EU Application MT
AstraZeneca's Application for COVID-19 Prevention Drug Wins Accelerated Review in EU MT
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
159.2 USD
Average target price
177.2 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. AstraZeneca Wins US FDA's Priority Review Tag for Expanded Use of Lung Cancer Drug